4//SEC Filing
Makhzoumi Mohamad 4
Accession 0001193125-25-232147
CIK 0001671284other
Filed
Oct 5, 8:00 PM ET
Accepted
Oct 6, 5:54 PM ET
Size
84.1 KB
Accession
0001193125-25-232147
Insider Transaction Report
Form 4
NeueHealth, Inc.NEUE
Makhzoumi Mohamad
Director10% Owner
Transactions
- Tax Payment
Common Stock
2025-10-02$6.75/sh−280$1,890→ 1,526,937 total(indirect: See Note 1) - Tax Payment
Common Stock
2025-10-02$6.75/sh−643$4,340→ 1,960,591 total(indirect: See Note 1) - Disposition to Issuer
Common Stock
2025-10-02−1,159,683→ 0 total(indirect: See Note 5) - Disposition to Issuer
Series B Convertible Perpetual Preferred Stock
2025-10-02−37,700→ 0 total(indirect: See Note 6)→ Common Stock (509,780 underlying) - Exercise/Conversion
Common Stock
2025-10-02$0.01/sh+434,297$4,343→ 1,961,234 total(indirect: See Note 1) - Exercise/Conversion
Common Stock
2025-10-02$0.01/sh+189,195$1,892→ 788,259 total(indirect: See Note 5) - Tax Payment
Common Stock
2025-10-02$6.75/sh−551$3,719→ 1,159,683 total(indirect: See Note 5) - Exercise/Conversion
Common Stock
2025-10-02$0.01/sh+189,195$1,892→ 488,982 total(indirect: See Note 6) - Exercise/Conversion
Common Stock
2025-10-02$0.01/sh+124,085$1,241→ 2,385,055 total(indirect: See Note 7) - Exercise/Conversion
Common Stock
2025-10-02$0.01/sh+607,536$6,075→ 2,261,870 total(indirect: See Note 7) - Award
Warrant (Right to Buy)
2025-10-02+434,297→ 434,297 total(indirect: See Note 1)Exercise: $0.01From: 2025-10-02Exp: 2030-10-02→ Common Stock (434,297 underlying) - Award
Warrant (Right to Buy)
2025-10-02+372,255→ 372,255 total(indirect: See Note 5)Exercise: $0.01From: 2025-10-02Exp: 2030-10-02→ Common Stock (372,255 underlying) - Award
Warrant (Right to Buy)
2025-10-02+124,085→ 124,085 total(indirect: See Note 7)Exercise: $0.01From: 2025-10-02Exp: 2030-10-02→ Common Stock (124,085 underlying) - Exercise/Conversion
Warrant (Right to Buy)
2025-10-02−124,085→ 0 total(indirect: See Note 7)Exercise: $0.01→ Common Stock (124,085 underlying) - Disposition to Issuer
Common Stock
2025-10-02−1,960,591→ 0 total(indirect: See Note 1) - Tax Payment
Common Stock
2025-10-02$6.75/sh−280$1,890→ 488,702 total(indirect: See Note 6) - Tax Payment
Common Stock
2025-10-02$6.75/sh−276$1,863→ 674,554 total(indirect: See Note 6) - Tax Payment
Common Stock
2025-10-02$6.75/sh−2,455$16,571→ 1,654,334 total(indirect: See Note 7) - Disposition to Issuer
Common Stock
2025-10-02−16,443→ 0 total - Exercise/Conversion
Warrant (Right to Buy)
2025-10-02−189,195→ 0 total(indirect: See Note 6)Exercise: $0.01→ Common Stock (189,195 underlying) - Disposition to Issuer
Series A Convertible Perpetual Preferred Stock
2025-10-02−75,000→ 0 total(indirect: See Note 6)→ Common Stock (330,194 underlying) - Disposition to Issuer
Common Stock
2025-10-02−674,554→ 0 total(indirect: See Note 6) - Exercise/Conversion
Common Stock
2025-10-02$0.01/sh+1,656,789$16,568→ 1,656,789 total(indirect: See Note 7) - Tax Payment
Common Stock
2025-10-02$6.75/sh−900$6,075→ 2,260,970 total(indirect: See Note 7) - Exercise/Conversion
Warrant (Right to Buy)
2025-10-02−186,128→ 0 total(indirect: See Note 6)Exercise: $0.01→ Common Stock (186,128 underlying) - Exercise/Conversion
Common Stock
2025-10-02$0.01/sh+189,195$1,892→ 1,527,217 total(indirect: See Note 1) - Disposition to Issuer
Common Stock
2025-10-02−43,678→ 0 total(indirect: See Note 4) - Tax Payment
Common Stock
2025-10-02$6.75/sh−280$1,890→ 787,979 total(indirect: See Note 5) - Exercise/Conversion
Common Stock
2025-10-02$0.01/sh+372,255$3,723→ 1,160,234 total(indirect: See Note 5) - Exercise/Conversion
Common Stock
2025-10-02$0.01/sh+186,128$1,861→ 674,830 total(indirect: See Note 6) - Disposition to Issuer
Common Stock
2025-10-02−2,384,873→ 0 total(indirect: See Note 7) - Exercise/Conversion
Warrant (Right to Buy)
2025-10-02−189,195→ 0 total(indirect: See Note 1)Exercise: $0.01→ Common Stock (189,195 underlying) - Exercise/Conversion
Warrant (Right to Buy)
2025-10-02−434,297→ 0 total(indirect: See Note 1)Exercise: $0.01→ Common Stock (434,297 underlying) - Exercise/Conversion
Warrant (Right to Buy)
2025-10-02−189,195→ 0 total(indirect: See Note 5)Exercise: $0.01→ Common Stock (189,195 underlying) - Exercise/Conversion
Warrant (Right to Buy)
2025-10-02−372,255→ 0 total(indirect: See Note 5)Exercise: $0.01→ Common Stock (372,255 underlying) - Award
Warrant (Right to Buy)
2025-10-02+186,128→ 186,128 total(indirect: See Note 6)Exercise: $0.01From: 2025-10-02Exp: 2030-10-02→ Common Stock (186,128 underlying) - Exercise/Conversion
Warrant (Right to Buy)
2025-10-02−1,656,789→ 0 total(indirect: See Note 7)Exercise: $0.01→ Common Stock (1,656,789 underlying) - Exercise/Conversion
Warrant (Right to Buy)
2025-10-02−607,536→ 0 total(indirect: See Note 7)Exercise: $0.01→ Common Stock (607,536 underlying) - Tax Payment
Common Stock
2025-10-02$6.75/sh−182$1,229→ 2,384,873 total(indirect: See Note 7) - Disposition to Issuer
Series A Convertible Perpetual Preferred Stock
2025-10-02−125,000→ 0 total(indirect: See Note 7)→ Common Stock (550,323 underlying) - Disposition to Issuer
Series B Convertible Perpetual Preferred Stock
2025-10-02−100,000→ 0 total(indirect: See Note 7)→ Common Stock (1,352,200 underlying)
Footnotes (14)
- [F1]The Reporting Person is a manager of NEA 15 GP, LLC ("NEA 15 GP"), which is the sole general partner of NEA Partners 15, L.P. ("NEA Partners 15"). NEA Partners 15 is the sole general partner of New Enterprise Associates 15, L.P. ("NEA 15"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 15 in which the Reporting Person has no pecuniary interest.
- [F10]The warrants became fully exercisable on October 2, 2025.
- [F11]The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions.
- [F12]The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions.
- [F13]The warrants became exercisable as to 828,395 shares on August 29, 2023, 552,263 shares on September 18, 2023, 100,606 shares on November 1, 2023 and 175,525 shares on December 20, 2023.
- [F14]The warrants became exercisable as to 371,187 shares on April 30, 2024, 28,399 shares on June 21, 2024, 185,595 shares on October 2, 2024 and 22,355 shares on September 26, 2025.
- [F2]Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025.
- [F3]Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. ("Parent") and NH Holdings Acquisition 2025, Inc. ("Merger Sub"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the "Merger"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. ("Ultimate Parent"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock ("Series A Preferred Stock") and Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist.
- [F4]The Reporting Person is a manager of NEA 15 GP, which is the sole general partner of NEA Partners 15-OF, L.P. ("NEA Partners 15-OF"). NEA Partners 15-OF is the sole general partner of NEA 15 Opportunity Fund, L.P. ("NEA 15-OF"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 15-OF in which the Reporting Person has no pecuniary interest.
- [F5]The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.
- [F6]The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.
- [F7]The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. ("NEA Partners 18 VGE"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.
- [F8]The warrants became exercisable as to 123,729 shares on April 30, 2024, 1,733 shares on June 21, 2024, 61,865 shares on October 2, 2024 and 1,868 shares on September 26, 2025.
- [F9]Warrants issued pursuant to the Warrantholders Agreement, dated September 30, 2025 between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, that certain Incremental Amendment No. 2, dated as of April 8, 2024, that certain Amendment No. 3, dated as of June 21, 2024, that certain Amendment No. 4, dated as of October 29, 2024, and that certain Amendment No. 5, dated as of September 30, 2025, between the Issuer and the lenders thereto.
Documents
Issuer
NeueHealth, Inc.
CIK 0001671284
Entity typeother
Related Parties
1- filerCIK 0001630226
Filing Metadata
- Form type
- 4
- Filed
- Oct 5, 8:00 PM ET
- Accepted
- Oct 6, 5:54 PM ET
- Size
- 84.1 KB